Neffy 1 mg, an epinephrine nasal spray, has been approved by the FDA for the treatment of type I allergic reactions, including anaphylaxis, in pediatric patients aged 4 years and older. This needle-free option addresses barriers associated with traditional autoinjectors and facilitates rapid administration. The FDA approval was based on clinical trial data demonstrating comparable pharmacokinetic and pharmacodynamic responses to epinephrine injection products. The product has a 24-month shelf life at room temperature and resistance to temperature extremes up to 122°F for 3 months. NeffyConnect, a support program, assists patients and providers with access, insurance navigation, and financial assistance, making it more accessible and affordable for patients in need.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
